Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib in IDH1-Mutated Malignancies and Hepatic or Renal Impairment
NCT07006688Phase 1Recruiting
- Sponsor
- Servier
- Start
- Jan 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of ivosidenib in malignancy (5 arms), sponsored by Servier. Primary endpoints: Maximum observed steady-state concentration, Area under the concentration time curve from 0 to 24 hours and 2 more. Started Jan 2026; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
malignancy
Beyond the preview
Go deeper on NCT07006688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07006688.